Review of the top 5 cardiology studies of 2013-14

Abstract

Get full access to this article

View all access options for this article.

References

Barry

Boswell

Law

. Review of the top 5 cardiology studies of 2011-12. Can Pharm J (Ott) 2013;146:213-7.

Eikelboom

Connolly

Brueckmann

, for the RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-14.

DeWilde

Oirbans

Verheuqt

, for the WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107-15.

Mauri

Kereiakes

Yeh

, for the DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155-66.

Pitt

Pfeffer

Assmann

, for the TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383-92.

McMurray

JJV

Packer

Desai

, for the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014:371:993-1004.

Dhalla

Gomes

Yao

. Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study. Ann Intern Med 2013;158:447-55.

Government of Canada. Pradaxa/Pradax (dabigatran etexilate)—new contraindication in patients with prosthetic heart valves requiring anticoagulant treatment due to their valvular status—for health professionals. Available: www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/16385a-eng.php (accessed March 12, 2015).

Nishimura

Otto

Bonow

. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:e57-185.

10.

Andrade

Deyell

Khoo

. Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention/stenting: a systematic review and meta-analysis. Can J Cardiol 2013;29:204-12.

11.

Karjalainen

Porela

Ylitalo

. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007;28:726-32.

12.

Lamberts

Gislason

Olesen

. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013;62:981-9.

13.

Pitt

Zannad

Remme

, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.

14.

Pitt

Remme

Zannad

, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.

15.

Zannad

McMurray

Krum

, for the EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.

16.

Moe

Ezekowitz

O’Meara

. The 2014 Canadian Cardiovascular Society heart failure management guidelines focus update: anemia, biomarkers and recent therapeutic trial implications. Can J Cardiol 2015;31:3-16.

17.

Rousch

Holford

Guddati

AK.

Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012;59:1110-7.

18.

van Blijderveen

Straus

Rodenburg

. Risk of hyponatremia with diuretics: chlorthalidone versus hydrochlorothiazide. Am J Med 2014;127:763-71.

19.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.